Questcor, MedPointe Inc. sales and marketing update

QSC acquired U.S. rights to MedPointe's Doral quazepam insomnia drug for $2.5 million in cash and a potential milestone of $1.5 million. QSC plans to relaunch the selective benzodiazepine receptor a...